Protagonist Therapeutics, Inc. Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.

PTGX

株式のランク #2307
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
株価
$134.35
時価総額
$8.69B
変化(1日)
4.35%
変化(1年)
73.35%
国
US
取引 Protagonist Therapeutics, Inc. (PTGX)

カテゴリー

Healthcare
Protagonist Therapeutics, Inc.(PTGX)の営業利益率
October 2026 時点の営業利益率 TTM: 20.69%
Protagonist Therapeutics, Inc. の最新の財務報告と株価によると、現在の営業利益率(TTM)は 20.69% です。2023 年末時点では -156.09% でした。
Protagonist Therapeutics, Inc. の営業利益率の履歴(2014 から 2026)
各年末の営業利益率
年 営業利益率 変化
2026 (TTM) 20.69% -64.45%
2024 58.20% -137.29%
2023 -156.09% -68.42%
2022 -494.24% 7.44%
2021 -460.01% 104.12%
2020 -225.36% -99.35%
2019 -34,857.58% 25,403.06%
2018 -136.68% -27.64%
2017 -188.89% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
同業他社の営業利益率
企業 営業利益率 営業利益率の差 国
38.59% -98.13%
US
-149.01% -107.20%
US
25.57% -98.76%
AU
0.00% -
CH
28.81% -98.61%
NL
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。